PARPi are currently being evaluated in two ongoing phase 2 trials: one trial assessing niraparib in BAP1-altered malignant mesothelioma and other DNA damage response-deficient neoplasms (NCT03207347), and another trial evaluating olaparib in separate cohorts of patients with malignant mesothelioma in accordance with the BAP1 status (NCT03531840); no results have been presented so far. Here, BAP1 is linked to malignant mesothelioma.